Marius Horger
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
31.01.2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
31.01.2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
Horger M, Pereira P, Claussen C, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol 2008; 81:386-96.
01.05.2008Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
01.05.2008Br J Radiol 2008; 81:386-96
Horger Marius, Pereira Philippe, Claussen Claus Detlef, Kanz Lothar, Vonthein Reinhard, Denecke Barbara, Driessen Christoph
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Hartmann J, Grünwald V, Kanz L, Käfer G, Pintoffl J, Meisinger I, Huober J, Horger M, Schleicher J, Mayer F, German sarcoma group. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861-6.
15.08.2007Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
15.08.2007Cancer 2007; 110:861-6
Hartmann Joerg T, Grünwald Viktor, Kanz Lothar, Käfer Gabriele, Pintoffl Jan, Meisinger Ines, Huober Jens, Horger Marius, Schleicher Jan, Mayer Frank, German sarcoma group
The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.
15.04.2007The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
15.04.2007Cancer 2007; 109:1617-26
Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph